Pfizer Inc (PFE)

PFE (NYSE:Drugs)
$30.09
pos +0.20
+0.67%
Today's Range: 29.92 - 30.22 | PFE Avg Daily Volume: 28,823,300
Last Update: 04/16/14 - 4:00 PM EDT
Volume: 29,427,173
YTD Performance: -2.42%
Open: $30.15
Previous Close: $29.89
52 Week Range: $27.12 - $32.96
Oustanding Shares: 6,382,925,343
Market Cap: 190,974,710,214
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 5
Moderate Buy 2 2 2 2
Hold 2 3 2 4
Moderate Sell 0 0 0 0
Strong Sell 1 0 1 1
Mean Rec. 1.86 1.68 1.86 2.13
Latest Dividend: 0.26
Latest Dividend Yield: 3.26%
Dividend Ex-Date: 02/05/14
Price Earnings Ratio: 19.35
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
19.35 9.40 28.47
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-4.14% -1.84% 45.59%
GROWTH 12 Mo 3 Yr CAGR
Revenue -12.50 -0.24 -0.09
Net Income 51.20 0.38 0.11
EPS 64.40 2.14 0.46
Earnings for PFE:
EBITDA 22.78B
Revenue 51.58B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $0.55 $0.57 $2.23 $2.29
Number of Analysts 10 8 13 11
High Estimate $0.58 $0.61 $2.31 $2.45
Low Estimate $0.53 $0.55 $2.13 $2.14
Prior Year $0.54 $0.56 $2.22 $2.23
Growth Rate (Year over Year) 1.67% 1.34% 0.42% 2.73%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Apr 11, 2014 | 11:41 AM EDT

Let's categorize things in this vicious rotation.

By

Dick Arms

 | Apr 10, 2014 | 7:00 AM EDT

Market declines typically end in fear, but we're seeing complacency.

By

Louis Grasso

 | Apr 8, 2014 | 2:45 PM EDT

Nah. Neither is it sexy, but in the long run it'll do you good.

By

Jared Dillian

 | Apr 8, 2014 | 11:00 AM EDT

I wouldn't buy this market with your money.

By

Jim Cramer

 | Apr 1, 2014 | 3:08 PM EDT

TheStreet's Jim Cramer says investors need to see money come back to high-growth names, which have seen a shrinking price-to-earnings multiple.

By

Jim Cramer

 | Apr 1, 2014 | 11:26 AM EDT

These fanciful folks, it seems, just want to make themselves feel better about missing last year's 'phony' rally.

By

Jim Cramer

 | Apr 1, 2014 | 9:14 AM EDT

Johnson & Johnson is selling its Ortho-Clinical Diagnostics business to The Carlyle Group for $4 billion.

By

Jim Cramer

 | Mar 29, 2014 | 8:00 AM EDT

TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.

By

Jim Cramer

 | Mar 28, 2014 | 6:00 PM EDT

Jim Cramer reveals how the same rules he discusses in his latest book, 'Getting Rich Carefully,' apply to his newest investment, Mexican restaurant Bar San Miguel in Carroll Gardens, Brooklyn.

By

Toni Turner

 | Mar 23, 2014 | 1:00 PM EDT

Thoroughly examine your sector brackets for higher profits.

Market posts the third day of solid gains in a row. Will see if we can make it four a row...
With the averages now flying upwards, and everyone scrambling to buy, it is startling to r...
Inability of Bank of America (BAC) to claw its way above 16.30-.40 resistance will increas...
The Fed works for the government. The Federal government owes over $16 trillion. The Fed w...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.